The delay in LOXL2 is also most concerning for me. It was arguably the closest inflection point, but the SP will probably drift now and the upside from the partnership (Whenever it eventutes) may be marginal compared to today. Still I’m hoping the delay is because management is trying to strike a good deal and the multiple indications is adding complexity to it. The main focus for Bronchitol will be the US. Chiesi has sunk a ton of cash to get the FDA to this point (and continues to do so), so there must be financial upside to it.
PXS Price at posting:
23.0¢ Sentiment: Hold Disclosure: Held
